Skip to content

Structure-Based Drug Repurposing of Some Broad-Spectrum Antiviral Drugs Against the ZIKV NS2B-NS3 Protease

Aug 2026 · Journal of Pharmaceutical Innovation · Vol 22 · 0 citations · 72 references

TL;DR

A structure-based computational drug repurposing strategy was employed to identify potential inhibitors of the ZIKV NS2B–NS3 protease and suggested acceptable drug-likeness and pharmacokinetic properties for Cpd 6 and other ligands and therefore, these findings are expected to provide valuable structural and dynamic insights that would guide future experimental validation and optimization of antiviral inhibitors targeting Zika virus infection.

View source

Similar papers

Open access Sep 2026

A combination of MD-derived pharmacophores and structure-based strategy identifies dual allosteric inhibitors of NS2B-NS3 proteases in Zika and West Nile viruses.

Starting from the crystal structure of a Zika virus (ZIKV) NS2B-NS3 protease with bound allosteric inhibitor, we generated dynamic pharmacophore models derived from representative molecular dynamics (MD) conformations to capture key interaction patterns. These models guided a pharmacophore-based virtual screening of co...

Antonio Lupia, Salvatore Nieddu, Laura Demuru et al. · 0 citations
Open access Aug 2026

In Silico Evaluation of Selective HDAC6 Inhibitors J27820 and J22352 Against Zika Virus Proteins: Molecular Docking and Dynamics Insights

The results of this study highlight the significant advantages of J27820 and J22352, emphasizing their potential for targeted inhibition and promising opportunities for developing effective antiviral therapies against the Zika virus.

Farid Elbamtari, Etibaria Belghalia, Mhamed Elbouhi et al. · 0 citations
Open access Aug 2026

Identification of Potential SARS-CoV-2 Main Protease (MPro) Inhibitors Through Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics Simulation Approaches

The findings suggest that Lig-1, followed by Lig-3, may serve as promising computational lead compounds targeting SARS-CoV-2 MPro, representing promising candidates for further experimental validation.

Mohd Yasir Khan, Farah Maarfi, A. Shah et al. · 0 citations
#explainable ai Open access Sep 2026

Molecular modeling design of antitrypanosomal pyrazolone derivatives targeting Chagas disease: QSAR, docking, molecular dynamics and free energy calculations

These findings support pyrazolones as antitrypanosomal scaffolds and provide structural hypotheses for future experimental validation against Cz, suggesting that contacts with S2/S3 subsite residues and conformational adaptability may contribute to Cz recognition but do not, alone, explain whole-cell potency.

Karen Karla F. Sousa, A. Barbosa, F. Cardoso et al. · 0 citations
Open access Aug 2026

Ligand‑Based Virtual Screening Discovery of Thienopyrimidinone Derivatives as Allosteric nSMase2 Modulators and Antivirals Against West Nile Virus

Orthoflaviviruses such as West Nile virus (WNV), Zika virus (ZIKV), or dengue virus (DENV) represent a growing global health threat, with millions of annual infections and no approved antiviral therapies. Targeting host pathways represents an alternative antiviral strategy that may overcome limitations associated with...

Hadrián Álvarez-Fernández, Patricia Mingo-Casas, Ana-Belén Blázquez et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.